NCT04488575View on ClinicalTrials.gov

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

May 16, 2021

Study Completion Date

May 19, 2021

Conditions
Covid19
Interventions
DRUG

EDP1815

EDP1815 is an orally administered monoclonal microbe

DRUG

Placebo

Placebo oral capsule

Trial Locations (4)

78539

DHR Health Institute, Edinburg

08901

Robert Wood Johnson University Hospital, New Brunswick

07103

The University Hospital, Newark

Unknown

Hacettepe University Adult Hospital, Ankara

Sponsors
All Listed Sponsors
lead

Evelo Biosciences, Inc.

INDUSTRY

NCT04488575 - Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection | Biotech Hunter | Biotech Hunter